IGF-1 LR3

IGF-1 LR3 (Long Arg3 Insulin-Like Growth Factor-1) is a recombinant, non-glycosylated polypeptide consisting of 83 amino acids, engineered as a structurally modified analog of native human insulin-like growth factor-1. ^(1,2) Native IGF-1 is a 70-amino-acid peptide produced primarily in the liver in response to growth hormone (GH) stimulation, and it mediates many of the anabolic, growth-promoting, and regenerative effects attributed to the GH/IGF-1 axis. ⁽¹⁾ IGF-1 LR3 was designed to overcome the primary limitation of native IGF-1: its extremely short biological half-life, caused by rapid sequestration by a family of six IGF-binding proteins (IGFBP-1 through IGFBP-6) that regulate IGF-1 availability in circulation. ⁽²⁾

The “LR3” designation refers to two deliberate structural modifications. The “Long” component is a 13-amino-acid extension added to the N-terminus of the peptide, increasing total chain length from 70 to 83 amino acids. The “R3” (Arg3) component is a substitution of arginine for the naturally occurring glutamic acid at position 3. ^(1,2) Together, these modifications reduce binding affinity to IGFBPs by 70-80%, meaning that a substantially greater proportion of administered IGF-1 LR3 remains free and biologically active in circulation compared to native IGF-1. ^(2,3) The practical result is an extension of biological half-life from approximately 10-15 minutes for native IGF-1 to 20-30 hours for IGF-1 LR3 in rodent plasma models. ⁽³⁾

Recombinant production of IGF-1 LR3 is typically carried out using engineered protein expression systems in Escherichia coli, followed by chromatographic purification and refolding to obtain a correctly folded polypeptide with three intact intramolecular disulfide bonds. ⁽¹⁾ The molecular weight, as determined by mass spectrometry, is approximately 9,111 daltons (9.1 kDa). ⁽¹⁾

IGF-1 LR3 is widely used in cell biology and molecular research as a potent growth factor in cell culture media and as a tool for studying IGF-1 receptor signaling, growth-factor analog design, and cellular regulatory mechanisms. ⁽¹⁾ It shares structural homology with insulin, which is why it retains the ability to interact (at high concentrations) with both the IGF-1 receptor and the insulin receptor, a property relevant to its metabolic and hypoglycaemic (also spelled hypoglycemic) effects. ^(4,6)

IGF-1 LR3 has never been evaluated in human clinical trials and is not approved by the FDA, the MHRA (UK), or the TGA (Australia) for any therapeutic indication. The only FDA-approved IGF-1 product is mecasermin (brand name Increlex), which is native recombinant human IGF-1 (not LR3) approved exclusively for severe primary IGF-1 deficiency in children. ⁽⁷⁾ Healius supplies IGF-1 LR3 as a lyophilized powder in 1mg vials, intended strictly for laboratory and research applications.

IGF-1 LR3 exerts its biological effects by binding to and activating the IGF-1 receptor (IGF-1R), a transmembrane receptor tyrosine kinase found on the surface of most cell types, including skeletal muscle, bone, cartilage, liver, kidney, and nervous tissue. ^(4,5) Receptor activation initiates two primary intracellular signaling cascades that drive the peptide’s anabolic and proliferative effects.

The first and most extensively studied pathway is the PI3K/Akt/mTOR cascade. Upon IGF-1R activation, phosphoinositide 3-kinase (PI3K) is recruited, which activates protein kinase B (Akt). Akt in turn activates the mammalian target of rapamycin (mTOR), a central regulator of protein synthesis, cell growth, and cellular metabolism. ^(4,5) The net effect is increased protein synthesis, improved glucose uptake, enhanced amino acid transport into muscle cells, and a positive nitrogen balance, all of which are fundamental to muscle tissue growth and repair.

The second pathway is the MAPK/ERK (mitogen-activated protein kinase / extracellular signal-regulated kinase) cascade. Research has demonstrated that Long R3 IGF-I stimulates cell proliferation through both ERK and PI3K signaling pathways, explaining IGF-1’s ability to drive hyperplasia, the creation of entirely new cells, rather than solely increasing the size of existing cells. ^(5,8) This dual mechanism of hyperplasia and hypertrophy distinguishes IGF-1 signaling from many other anabolic pathways and is the primary reason the peptide attracts research interest in muscle biology.

A critical feature of IGF-1 LR3’s mechanism is its activation of satellite cells, the resident stem cells of skeletal muscle tissue. ^(3,5) Satellite cells normally exist in a quiescent state on the surface of muscle fibers. When activated by IGF-1R signaling, they proliferate and differentiate, either fusing with existing muscle fibers (contributing to hypertrophy) or forming entirely new muscle fibers (hyperplasia). Published preclinical data have shown a 25-30% increase in satellite cell proliferation markers (Ki-67, MyoD) following IGF-1 LR3 administration in laboratory models. ⁽³⁾

IGF-1 LR3 also functions as a myostatin inhibitor by activating MyoD, a myogenic regulatory factor that counteracts myostatin’s inhibitory effects on muscle growth. ⁽⁹⁾ Additionally, the peptide influences metabolic pathways by enhancing glucose uptake and nutrient partitioning, directing calories preferentially toward muscle tissue rather than fat storage. At supraphysiological concentrations, IGF-1 LR3 cross-reacts with the insulin receptor, contributing to its glucose-lowering (hypoglycaemic) effects and explaining the most commonly reported side effect: hypoglycemia. ^(4,6)

IGF-1 LR3 has been extensively studied in preclinical and in vitro research settings, with the majority of published evidence focusing on muscle cell biology, tissue regeneration, and growth factor signaling. It is important to state clearly that no human clinical trials of IGF-1 LR3 have been conducted, and all efficacy data come from animal models and cell culture systems. ^(3,6)

Tomas et al.  ^{(1993, 1996)} published foundational studies demonstrating that LR3 IGF-I analogs, which bind poorly to IGF-binding proteins, exhibit superior potency compared to native IGF-1 when infused in animal models and when administered by injection. ^(10,11) These studies established the pharmacological rationale for why reduced IGFBP binding translates into greater in vivo biological activity: the free peptide reaches target tissues for longer durations.

In skeletal muscle research, published preclinical data have demonstrated measurable effects on multiple endpoints. Satellite cell activation, measured by Ki-67 proliferation markers, showed a 25-30% increase following IGF-1 LR3 treatment. Myotube formation in vitro was enhanced by approximately 20%. Muscle fiber cross-sectional area in mouse models increased by 15-20%. ⁽³⁾ These findings support the dual hyperplasia/hypertrophy model: IGF-1 LR3 both creates new muscle cells and enlarges existing ones through parallel signaling pathways.

Adams et al., publishing in the Journal of Applied Physiology, demonstrated that IGF-1 induces proliferation and differentiation of muscle satellite cells, enabling hypertrophic adaptations in response to overload. ⁽⁵⁾ This research established the mechanistic link between IGF-1R activation, satellite cell biology, and functional muscle growth in experimental models.

The closest human clinical data comes from mecasermin (Increlex), the FDA-approved recombinant native IGF-1 product used to treat severe primary IGF-1 deficiency in children. ⁽⁷⁾ Chernausek et al.  ⁽²⁰⁰⁷⁾ documented that long-term mecasermin treatment produced significant improvements in linear growth velocity, providing proof-of-concept that sustained IGF-1R activation drives measurable growth outcomes in humans. ⁽⁷⁾ However, mecasermin is native IGF-1 (70 amino acids), not IGF-1 LR3 (83 amino acids), and extrapolation from one to the other requires caution. The mecasermin data are relevant primarily for understanding the side-effect profile of sustained IGF-1 pathway activation, particularly the risks of hypoglycemia and tissue overgrowth. ⁽⁷⁾

Regarding the highly searched “before and after” query: no standardized, peer-reviewed human before-and-after data exists for IGF-1 LR3—anecdotal reports circulating online lack medical verification, controlled conditions, and standardized protocols. The preclinical muscle data summarized above represent the most reliable evidence base for IGF-1 LR3’s effects on muscle tissue.

IGF-1 LR3 and IGF-1 DES (Des (1-3) IGF-1) are both modified analogs of native IGF-1, but they differ fundamentally in half-life, potency, mechanism of delivery, and research applications. ⁽¹²⁾

IGF-1 LR3 has a long systemic half-life of 20-30 hours due to its reduced affinity for IGFBPs. When administered subcutaneously, it circulates throughout the body and activates the IGF-1 receptor systemically across multiple tissue types. This makes it suitable for research into whole-body growth factor signaling, metabolic effects, and generalized anabolic responses. ^(2,3)

IGF-1 DES is a truncated form of IGF-1 missing the first three N-terminal amino acids (hence “Des (1-3)”). This modification makes it approximately 10 times more potent at the IGF-1 receptor than native IGF-1, but it has an extremely short half-life of only 20-30 minutes. ⁽¹²⁾ Because of this short duration, IGF-1 DES is typically administered via intramuscular injection directly into target muscle tissue, where it produces intense but localized effects before rapid clearance. This makes it more suited to research on localized tissue responses rather than systemic growth factor biology.

The trade-offs between the two variants are straightforward. IGF-1 LR3 offers sustained, systemic activity with once-daily dosing and a broader research application profile. Still, it carries a greater risk of systemic side effects, including hypoglycemia, due to its prolonged circulation time. IGF-1 DES offers intense, localized receptor activation with rapid clearance and a potentially lower systemic side effect profile, but requires site-specific injection and multiple daily administrations for sustained effects. Both variants are WADA-prohibited under S2 (Peptide Hormones, Growth Factors, and Related Substances) at all times. ⁽¹³⁾

Researchers frequently compare IGF-1 LR3 with growth hormone-releasing peptides (GHRPs) and growth hormone-releasing hormone (GHRH) analogs because both classes ultimately influence the GH/IGF-1 axis. However, they operate at fundamentally different points in the signaling cascade, and understanding this distinction is critical for protocol design. ⁽⁴⁾

IGF-1 LR3 acts downstream by directly activating the IGF-1 receptor. It bypasses the hypothalamus, pituitary, and liver entirely, delivering the end-effector molecule (IGF-1) straight to target tissues. This produces direct, potent anabolic signaling but also carries the risks associated with supraphysiological IGF-1R activation, particularly hypoglycemia and unregulated cell proliferation. ^(4,6)

Growth hormone-releasing peptides and GHRH analogs act upstream by stimulating the pituitary gland to release the body’s own growth hormone, which then triggers hepatic IGF-1 production through the natural feedback-regulated pathway. This approach is indirect but preserves the body’s endogenous regulatory mechanisms. Products in this category include Sermorelin (a GHRH analog), Ipamorelin (a selective GHRP), CJC-1295 (a long-acting GHRH analog), and Tesamorelin (a GHRH analog FDA-approved for HIV-associated lipodystrophy).

The CJC-1295 + Ipamorelin blend is one of the most commonly researched GH-releasing combinations, pairing sustained GHRH signaling (CJC-1295) with selective GH pulse amplification (Ipamorelin). This combination stimulates endogenous GH and IGF-1 production through natural pathways, offering a milder and more physiologically regulated approach compared to direct IGF-1R activation with IGF-1 LR3.

Stacking IGF-1 LR3 with GH-releasing peptides is a frequently discussed research protocol. The rationale is that GH-releasing peptides support endogenous GH/IGF-1 production while IGF-1 LR3 provides additional direct receptor activation. PEG-MGF (PEGylated Mechano Growth Factor) is another growth factor peptide commonly paired with IGF-1 LR3 in research contexts, as PEG-MGF promotes satellite cell proliferation through a complementary IGF-1 splice variant pathway.

The choice between direct IGF-1R activation and indirect GH stimulation depends on the research objective. Studies investigating downstream IGF-1 receptor biology, satellite cell responses, or metabolic effects of sustained IGF-1 exposure use IGF-1 LR3. Studies investigating pituitary-level GH regulation, pulse dynamics, or more physiologically conservative protocols typically use GHRP and GHRH analogs.

IGF-1 LR3 has a meaningful side-effect profile that researchers must understand before designing protocols. Unlike many research peptides with relatively benign safety data, IGF-1 LR3 has well-documented risks derived from its potent, sustained activation of the IGF-1 receptor and cross-reactivity with the insulin receptor. ^(6,7)

Hypoglycemia is the most common and clinically significant adverse effect. IGF-1 enhances glucose uptake into muscle cells and suppresses hepatic glucose output, producing insulin-like effects on blood sugar. In mecasermin (native IGF-1) clinical trials, symptomatic hypoglycemia occurred in approximately 40-50% of patients. ⁽⁷⁾ IGF-1 LR3’s extended 20–30-hour half-life means that hypoglycaemic episodes can occur multiple times throughout the day and may be particularly dangerous in fasted states or during exercise. ⁽⁶⁾ Symptoms include lightheadedness, shakiness, fatigue, blurred vision, and in severe cases, loss of consciousness.

Cancer risk is a serious consideration in IGF-1 research. Because IGF-1 promotes cellular proliferation broadly rather than selectively, it can stimulate the growth of pre-existing abnormal or precancerous cells. Pollak ⁽²⁰⁰⁴⁾, publishing in Nature Reviews Cancer, provided a comprehensive review of the IGF system’s role in neoplasia, establishing the mechanistic basis for the cancer concern. ⁽¹⁴⁾ Epidemiological evidence from Guevara-Aguirre et al.  ⁽²⁰¹¹⁾ studying individuals with Laron syndrome (growth hormone receptor deficiency resulting in extremely low IGF-1 levels) found a remarkably low incidence of cancer in this population, providing indirect but compelling evidence for the link between IGF-1 signaling and cancer risk. ⁽¹⁵⁾

Additional reported side effects from preclinical research and the clinical experience with mecasermin include joint pain and stiffness, peripheral edema (fluid retention), injection-site reactions, headache, and tonsillar/adenoidal hypertrophy. ⁽⁷⁾ With prolonged or excessive use, acromegaly-like changes (enlarged jaw, hands, and internal organs) are a theoretical risk, though these have not been documented in short-cycle research protocols. ⁽⁶⁾

Receptor desensitization (also spelled desensitization) occurs with continuous IGF-1 LR3 administration, reducing the peptide’s effectiveness over time. This is why cycling protocols (4-6 weeks on, equal time off) are standard in research contexts, to allow IGF-1 receptor sensitivity to recover. ⁽⁶⁾

IGF-1 LR3 is not FDA-approved for any indication. It is not classified as a controlled substance (no DEA schedule). It is prohibited by WADA under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) at all times, both in-competition and out-of-competition. ⁽¹³⁾ All forms of exogenous IGF-1 are prohibited, and athletes subject to anti-doping testing must avoid IGF-1 LR3 entirely. All research involving IGF-1 LR3 should be conducted with appropriate protocols and oversight.

1. PeptideSciences. IGF1 LR3 Information: Recombinant non-glycosylated polypeptide, 83 amino acids, structural modifications, E. coli expression system, molecular weight 9,116 Da. January 2026.

2. Francis GL, et al. Novel recombinant fusion protein analogs of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology. 1992;8(3):213-223.

3. Protide Health. IGF-1 LR3 Peptide: 2026 Research Guide. Preclinical data: satellite cell proliferation markers show a 25-30% increase, myotube formation is 20% higher, and fiber cross-sectional area increases by 15-20% in mouse models. January 2026.

4. Yoshida T, Delafontaine P. Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cells. 2020;9(9):1970. PMC7564018.

5. Adams GR, et al. IGF-1 induces proliferation and differentiation of muscle satellite cells, enabling hypertrophic adaptations in response to overload. Journal of Applied Physiology. Referenced in multiple satellite cell biology reviews.

6. GLPbase. IGF-1 LR3: The Complete Guide. Comprehensive review of dosing, safety, FDA/WADA status, and clinical parallels to mecasermin. March 2026.

7. Chernausek SD, et al. Long-term treatment with recombinant IGF-I in children with severe IGF-I deficiency due to growth hormone insensitivity. Journal of Clinical Endocrinology and Metabolism. 2007;92(3):902-910. (Mecasermin/Increlex safety and efficacy data.)

8. Bhardwaj G, et al. Extracellular signal-regulated kinase and phosphoinositol-3 kinase mediate IGF-1 induced proliferation of fetal cardiomyocytes. Long R3 IGF-I demonstrated activation of the ERK and PI3K pathways, driving hyperplasia.

9. IGF-1 activation of MyoD as a myostatin inhibitor. Referenced in multiple myogenic regulatory factor studies and the Exploring Peptides comprehensive review. January 2026.

10. Tomas FM, et al. Metabolic effects of insulin-like growth factor-I (IGF-I) and IGF-I variant [LR3IGF-I] in rats. Growth Regulation. 1993;3(1):26-29.

11. Tomas FM, Lemmey AB, Read LC, Ballard FJ. Superior potency of infused IGF-I analogs, which bind poorly to IGF-binding proteins, is maintained when administered by injection. Journal of Endocrinology. 1996;150(1):77-84.

12. IGF-1 DES (Des(1-3) IGF-1): truncated IGF-1 variant, 10x receptor potency, 20–30-minute half-life, localized delivery. Peptide Protocol Wiki and Swolverine comparative reviews. 2025-2026.

13. USADA. IGF-1 and the World Anti-Doping Agency Prohibited List. All forms of exogenous IGF-1 are prohibited at all times under S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. WADA Prohibited List 2026.

14. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nature Reviews Cancer. 2004;4(7):505-518.

15. Guevara-Aguirre J, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, as well as in cancer and diabetes in humans. Science Translational Medicine. 2011;3(70):70ra13.

16. LeRoith D, et al. IGF-1 administration increases glucose disposal and insulin sensitivity but also increases the risk of hypoglycemia, particularly in fasted states. Trends in Endocrinology and Metabolism. Referenced in multiple IGF-1 safety reviews.

17. Swolverine. Side Effects of IGF-1 Peptides: What to Watch Out For. Comprehensive safety review of LR3 and DES variants. July 2025.

This product is sold strictly for laboratory and research use only. It is not intended for human or animal consumption. It is not a dietary supplement, food, drug, or cosmetic. It is not intended to diagnose, treat, cure, or prevent any disease or condition. The buyer assumes all responsibility for the lawful use of this product in accordance with all applicable local, state, national, and international laws and regulations. By purchasing this product, the buyer confirms that they are a qualified researcher or are purchasing on behalf of a research institution.